UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043790
Receipt number R000049991
Scientific Title Clinical trial on improving children's QOL through the intestinal environment
Date of disclosure of the study information 2021/03/31
Last modified on 2022/04/01 16:09:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical trial on improving children's QOL through the intestinal environment

Acronym

Clinical trial on improving children's QOL through the intestinal environment

Scientific Title

Clinical trial on improving children's QOL through the intestinal environment

Scientific Title:Acronym

Clinical trial on improving children's QOL through the intestinal environment

Region

Japan


Condition

Condition

Healthy Children

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the effect of improving children's QOL through the intestinal environment by ingesting kestose.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

KINDL score

Key secondary outcomes

Average number of bowel movements per week (according to a questionnaire)
Fecal properties (by Bristol stool scale / questionnaire)
Changes in the intestinal flora in feces
Changes in the copy number of intestinal bacteria in feces
Changes in short-chain fatty acids in feces


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake 2 g of kestose daily for 12 weeks

Interventions/Control_2

Intake 2 g of maltose daily for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

3 years-old <=

Age-upper limit

7 years-old >

Gender

Male and Female

Key inclusion criteria

1.Persons whose substitute (guardian) have consented to participate in the trial
2.Japanese who are 3 years old or older and less than 7 years old and first or second year of kindergarten at the time of obtaining consent from their guardian

Key exclusion criteria

1.Persons who have a chronic illness and plan to start, end or change drug treatment during the study period, or those who have a history of serious illness
2.Persons who are allergic to test foods
3.Persons who plan to start or end new intake of probiotics / prebiotics or foods during the study period
4.Persons who used antibacterial drugs within 2 months at the start of the test
5.Persons who are judged to be ineligible by the judgment of the principal investigator or the research coordinator

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Yamashita

Organization

School Corporation Ohkagakuen

Division name

Nagoya College

Zip code

470-1193

Address

48 Takeji, Sakae-cho, Toyoake-shi, Aichi, JAPAN

TEL

0562-97-1306

Email

yamashita@nagoyacollege.ac.jp


Public contact

Name of contact person

1st name Mayuko
Middle name
Last name Takahashi

Organization

B food science Co., Ltd.

Division name

Research Unit Research and Development Center

Zip code

478-0046

Address

24-12, Kitahama-machi, Chita-shi, Aichi, JAPAN

TEL

0562-55-1734

Homepage URL


Email

m-takahashi@bfsci.co.jp


Sponsor or person

Institute

School Corporation Ohkagakuen

Institute

Department

Personal name



Funding Source

Organization

B food science Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Healthcare Systems Co., Ltd.

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

Tel

03-6809-2722

Email

soumu@hc-sys.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 03 Month 23 Day

Date of IRB

2021 Year 03 Month 23 Day

Anticipated trial start date

2021 Year 05 Month 24 Day

Last follow-up date

2021 Year 09 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 03 Month 31 Day

Last modified on

2022 Year 04 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049991


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name